Valeant ups the ante

Share this article:

Valeant's effort to take over Allergan got a push Monday with reports that Pershing Square Management, which along with Valeant is looking to take over Allergan, wants shareholders to meet. The Wall Street Journal notes that Valeant wants the meeting to vote out six members of Allergan's board.

The WSJ uncovered the shareholder meeting in a regulatory filing.

Allergan has encouraged shareholders to refuse Valeant's offers, which rose from $49.4 billion on Thursday to $52.7 billion in cash and stock on Friday.

The WSJ says Pershing has not identified the six board members it wants to show the door, but said Pershing needs support from shareholders who represent a total of 25% of the company's stock for the meeting to occur.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.